ReNeuron Group plc ReNeuron's lead cell line shows further potential (4082E)

TIDMRENE

RNS Number : 4082E

ReNeuron Group plc

18 October 2018

 
 AIM: RENE      18 October 2018 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

ReNeuron's lead cell line shows further potential

New data shows ReNeuron's lead CTX cell therapy candidate can be

re-programmed into a pluripotent state and differentiated into other cell types

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to its CTX stem cell platform will be presented today at the 26(th) Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Lausanne, Switzerland.

Dr Steve Pells, Principal Investigator at ReNeuron, will present data demonstrating for the first time that the Company's proprietary, conditionally immortalised, human neural stem cell line (CTX), currently undergoing clinical evaluation for the treatment of stroke disability, can be successfully re-programmed to a pluripotent state (that is, to an embryonic stem cell-like state enabling differentiation into any cell type). The poster presentation will also show that CTX-iPSCs (induced pluripotent stem cells) can be successfully differentiated along a different lineage from the original cell line (specifically, a mesenchymal stem cell line), and critically that ReNeuron's immortalisation technology remains functional in the reprogrammed pluripotent cells.

These results, albeit early stage, are particularly encouraging as they demonstrate that CTX, a well-characterised, clinical-grade neural stem cell line, could be used to produce new conditionally immortalised allogeneic (i.e. non-donor-specific) cell lines from any of the three germ layers: ectoderm, mesoderm and endoderm. ReNeuron will now look to develop further new allogeneic cell lines, including NK and T-cells (the cells that can be modified to attack cancer cells), as potential therapeutic agents for licensing to third parties.

Further information about this conference may be found at http://www.isscr.org/meetings-events/international-symposia/lausanne-2018.

Commenting on the data, Dr Randolph Corteling, Head of Research at ReNeuron, said:

"The data we are presenting at the ESGCT Annual Congress represents a significant advance in the use of cell re-programming to generate new allogeneic cell lines as potential therapeutic candidates. Importantly, the possibility of generating an allogeneic source of haematopoietic stem cells from our clinical-grade CTX cell line offers the prospect of a potential non-patient-specific alternative to those cancer immunotherapies in development that currently rely on the use of the patient's own T-cells."

ENDS

Enquiries:

 
                                               [phone] 
 ReNeuron                                       8400 
 Olav Hellebø, Chief Executive Officer 
 Michael Hunt, Chief Financial Officer 
 
                                                 [phone] 
   Buchanan                                                 5000 
 Mark Court, Sophie Wills, Tilly Abraham 
 
 Stifel Nicolaus Europe Limited 
  Jonathan Senior, Stewart Wallace, Ben        [phone] 
  Maddison (NOMAD and Joint Broker)             7600 
 
 N+1 Singer Advisory LLP                         [phone] 
  Mark Taylor (Joint Broker)                     3000 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

UPDGGGWUUUPRPGM

(END) Dow Jones Newswires

October 18, 2018 02:01 ET (06:01 GMT)